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Summary.-Protection tests using passively administered antibody have been car-
ried out using 2 mouse lymphomata. The classic model (" Gorer System ") used
alloantiserum which was absorbed in vivo to make it tumour specific before use.
In order to provide a system suitable for our work, the model was changed by step-
wise transitions to tumour specific immunoglobulin made from xenoantiserum
absorbed in vitro, since such a procedure is also applicable to human patients. The
time lapse used between challenge and treatment in the allo-system was generally
± 2 h but in the xeno-system could be extended to + 18 h. The xenoantisera could
not be absorbed in vivo but required 3 to 5 x 103 spleens per 100 ml serum to absorb
in vitro to render them tumour specific. The protective antibody was in the IgG
(not IgM) fraction of serum. Maximal tumour specific antibody (measured by
in vivo protection) appeared after the third injection of rabbits for one lymphoma,
but after the fifth for another. The sera were not cross-reactive among 3 lympho-
mata tested, of which 2 were of the same H-2 genotype.
ANTIBODIES against tumour specific
antigens providethe onlyspecifically direc-
ted "arrows " for tumour cell targets but
their clinical usefulness is far from clari-
fied. When administered passively they
are not sufficiently toxic to have much
effect on an established tumour; ways
ofincreasing their effectiveness have been
studied but the current trend is to
stimulate a host's own active cell mediated
immunity to tumours. In contrast, in
this and the following paper studies of
passive humoral immunity are reported.
The nonspecific immunosuppression
which is known to accompany tumour
growth is not properly understood (Row-
land et al., 1971) but it weighs against
stimulation of active immunity, as does
much of the treatment in cancer which
relies on cytotoxic drugs which are
themselves immunosuppressive and other
treatment, for example x-irradiation,
which has similar effects. Yet it is
accepted on the basis of experimental
results that the immune status of a
cancer patient, if properly understood,
could be of paramount importance for
prognosis.
Immunological protection against
strain-specific tumour challenge has been
described for many different mouse trans-
plantable tumours. For example Gorer
and Amos (1956) used alloantisera ab-
sorbed in vivo to protect mice against
their own lymphomata and many other
workers have used this and similar
systems. In this paper transitions are
made from alloantiserum to xenoantisera
(as Ig) and from in vivo absorption to in
vitro absorption, in order to provide a
model system suitable for the particular
purpose of testing the interactions of
drugs and antibodies (Davies, Buckham
and Manstone, 1974a; Davies et al.,
1974b).
MATERIALS AND METHODS
Animals and tumours.-EL4 is a lymph-
oma of C57BL mice which was originally
induced with dimethylbenzanthracene (GorerD. A. L. DAVIES, A. J. MANSTONE AND S. BUCKHAM
and Amos, 1956) and grows readily as an
ascites tumour. EL4 has been extensively
studied serologically and has been claimed
to have 3 distinguishable specificities not
possessed by C57BL/6 mice: These are " X "
(Gorer and Amos, 1956), " E " (Aoki et
at., 1970) and " L " (Leclerc et al., 1970).
These cells are TL negative (Boyse, Stockert
and Old, 1968). The lymphoma SB1 arose
spontaneously in a Balb/c mouse in our
colony; it does not grow as an ascites tumour
but enlarges the spleen up to 2 g (wet weight)
if injected intraperitoneally or subcutane-
ously; it does not grow at the site ofinjection.
About 5 cells constitutes a lethal dose in
the syngeneic host but 107 cells fail to grow
even in other H-2d mice (DBA/2, BIO.D2).
All mice were bred in our own colony.
For purposes of immunization rabbits were
bought from an accredited dealer.
Immunization.-Antisera were recovered
by standard methods but the immunization
schedules were varied over a series of experi-
ments and are detailed, where necessary,
under the different tests described below.
Groups of mice or rabbits were used as
recipients for immunization with tumour
cells, with normal cells as control, and are
described in the text where necessary.
Cytotoxicity.-The cytotoxicity of allo-
and xenoantisera was assessed on appro-
priate target cells (lymph node cells or tumour
cells) by release of 51Cr label from the cells
in the presence of complement. Generally
guinea-pig complement has been used and
tubes were incubated for 1 h. However, in
cases where it has been difficult to obtain a
cytotoxic titre against tumour target cells
(when none remained after absorption for
lymph ncde cells), rabbit complement has
been used and incubation times were in-
creased up to 3 h. The test system has
been described elsewhere (Albert and Davies,
1973).
Immunofluorescence.-The interaction of
tumourspecific rabbit antisera and lymphoma
cells was followed in some instances by
indirect fluorescence, using a fluorescein
conjugated goat anti-rabbit IgG (Flow Labo-
ratories, Irvine KA12 8NB, Scotland, Meloy
reagent C406).
Absorption.-In the earlier series of tests
described using alloantisera, absorption was
carried out in vivo; 1 ml of alloantiserum
was injected intraperitoneally into each of a
batch of C57BL/6 (for EL4) or Balb/c (for
SB1) mice, which were bled from the heart
4 h later. Some serological studies on such
absorbed alloantisera have already been
described (Davies and O'Neill, 1973).
It was found that even quite small
amounts (0-1 ml) of xenoantiserum injected
intraperitoneally in mice could not be
absorbed owing to some in vivo handling
problem. After 4 h, serum could still be
recovered from the peritoneal cavity retaining
almost its original titre; these sera were
frequently also toxic for mice. Some allo-
and all xenoantisera were therefore ab-
sorbed in vitro, mainly using spleen cells
but in some cases using liver or membrane
preparations (" eluate ") (Davies, 1966) from
lymphoid tissue. Both liver cell suspensions
and eluate were quite difficult to pack down
sufficiently by centrifugation in order to
avoid substantial losses of absorbed serum
volume. In any event, absorption was
taken to completion as tested by complement
mediated cytotoxicity for normal cells
(checked ifnecessary with rabbit complement
and a 3 h incubation time). Thus, for
example a serum having a titre of 1/1000
against C57BL/6 lymphocytes was diluted
1: 2 with saline to give a volume of 76 ml
and was absorbed thus: with 2f3 g eluate
the titre reduced to 1: 200, with a further
1f9 g to 1: 10 and subsequently with 25
C57BL/6 spleens the titre was reduced to
zero. Further absorption data were given
by Davies and O'Neill (1973).
As will be seen later in the text, the
amount of absorption required depended on
the number of injections given to raise a
particular serum. In all experiments, anti-
sera were submitted to small scale absorption
tests to determine likely requirements before
committing whole batches. Generally 3 or
4 absorption stages were needed to remove
all cytotoxicity for normal cells. Each
stage was monitored in order not to add
absorbing material in excess with the pros-
pect of losing tumour specific antibody non-
specifically. When spleens alone were used,
3000-5000 were usually required to absorb
fully 100 ml of antiserum. All absorptions
included material from mice of the same
H-2 genotype as that ofthe tumour cell used
for immunization. Thus, spleens from a
variety of mouse strains were used for the
bulk absorptions but some H-2d spleens were
always included in absorptions of EL4
antisera and some H-2d spleens always
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included in absorptions of SB1 antisera.
This was to remove xeno-antibodies having
individualrecognition discrimination (Staines
et al., 1973). All sera were centrifuged at
80,000 g for 60 min before use.
Fractionation.-Sera were fractionated
with ammonium sulphate (AmSO4) by pre-
cipitation at 40% saturation at 4°C. The
40% precipitate was recovered after several
hours of equilibration, re-dissolved and re-
precipitated at the same level a second time.
The precipitate was then washed with 40%
AmSO4, centrifuged out and re-dissolved for
dialysis and recovery. The quality of the
immunoglobulin and an assessment of loss
and recovery were made by checking this
rabbit Ig by immunodiffusion with a goat
Ig anti-rabbit Ig.
Protection tests.-Antisera or their im-
munoglobulin fractions were tested for their
ability to interfere with the growth of
lymphomata in vivo after suitable absorption
until non-reactive with normal cells. The
severity of the tests was adjusted as neces-
sary by selecting numbers of cells for chal-
lenge, by selecting routes (intraperitoneal or
subcutaneous), by adjusting the time lapse
between challenge and treatment and by
altering as necessary the number oftreatment
doses. Groups of mice varied from 5 to
15 (depending on the availability of serum)
and the day ofdeath recorded. The different
schedules of treatment are given in the
appropriate places in the text. The challenge
doses were based on the data given in Fig. la
for intraperitoneal doses of EL4 in C57BL/6
mice and in Fig. lb for SB1 in Balb/c mice.
RESULTS
The allogeneic system
The " Gorer " sytem using alloanti-
body, in vivo absorption and administra-
tion of whole serum, has been used before
to show that EL4 tumour specificity is
in the surface membrane material (Davies,
1963). More recently anti-EL4 alloanti-
sera were compared with antiserum pre-
pared by immunization with neuramini-
dase treated EL4 cells; the neuraminidase
treated cells did not give a serum that
was in any way superior to that following
immunization with untreated cells. This
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FIG. la. Challenge dose levels. EL4 lymphoma cells given intraperitoneally to C57BL/6 mice:
number of cells, A, 105; B, 104; C, 103; D, 102; E, 5 cells; F, 1 cell.
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FIG. lb. Challenge dose levels. SB1 lymphoma cells given intraperitoneally to Balb/c mice: A, 103
cells: B, 102 cells; C, 5 cells.D. A. L. DAVIES, A. J. MANSTONE AND S. BUCKHAM
test is not illustrate(d because somewhat
similar data were given previously and
the serology of this system has already
been described; there is an advantage in
using neuraminidase treated EL4 cells as
targets in the cytotoxicity tests (Davies
and O'Neill, 1973). Whole serum was
given to groups of mice in 0 5 ml injections
intraperitoneally and 2 h later 2 5 x 104
cells were given subcutaneously as the
challenge. There were 5000 survivors
following treatment with both anti-EL4
and anti-EL4 (neuraminidase treated)
groups of mice. These survivors were re-
challenged 105 days later with 105 EL4
cells subcutaneotusly (and also a group
ofC57BL/6 normal mice similarly treated),
but all died, showing that no immunity
had accrued from the first challenge with
tumour cells.
In order not to confine experiments
to the single lymphoma EL4, SB1 was
tested in a similar situation to that
previously described for EL4. C3H mice
were immunized with SB1 live cells,
Balb/c spleen cells or Balb/c thymus
cells. Nine injections were given and
the sera absorbed in vivo by giving 1 ml
intraperitoneally to each of 20 Balb/c
mice; these were bled after 4 h and 9 ml
of absorbed serum recovered. This was
tested for cytotoxicity on normal Balb/c
lymphocytes and thymnocytes and seen
to be zero.
Groups of mice were challenged with
103 SB1 cells 2 h after intraperitoneal
injection of 0 5 ml of absorbed serum.
It can be seen from Fig. 2 that the anti-
thymus and anti-spleen sera were without
any protective effect but serum against
SBI living cells gave a measurable delay
of death from tumour growth. This and
all subsequent tests indicated that it was
much more difficult to protect against
SBI than EL4, but the relative difficulty
and ease of protection provided two
situiations ofvalue for tests to be described
later. Using alloantisera against SB1,
we have only with some difficultv been
able to find a cytotoxic titre for SB1
target cells usinig sera absorbed to be
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Fi(. 2. Protection of Balb/c mice against
103 SBL cells, by alloantibodly Ina(le with
SBI live cells as immtunogen ia. C3H mice,
* *. Injections of saline, 0 O;
of C3H aniti-Balb/c spleen cell sertum,
of C3H aiiti-Balh/c thyrnus
sertim, LII.
non-cytotoxic for normal Balb/c lympl
node cells.
Changes tn test conditions
Passive immunity for human patients
would necessarily employ xenoantiserum,
in vitro absorption and administration of
the immunoglobulin fraction of serum.
Before testing mouse tumour xenoanti-
serum, alloantiserum of known protective
value against SBI tumour cells wlas made
and uised in a series of tests leading to the
following scheme.
Serum was obtained from 150 C3H
mice which had received 8 injections of
107 SBl cells. The titre against Balb/c
lymphocytes was 1/1200. Serum (62 ml)
was absorbed overnight at 4°C at a level
of 5 spleens/ml. This absorbed serum
was unreactive with Balb/c lymphocytes
(using guinea-pig complement and a 3 h
incubation time). There was a cytotoxic
titre against SB1 cells with this allo-
derived serum using guinea-pig comple-
ment and a 3 h incubation period (see
below). This is not shown because it
was similar in magnitude to that already
illustrated for EL4 (Davies and O'Neill,
1973). This absorbed alloantisertum was
fractionated to yield 7-5 ml of immuno-
globulin at 20 mg/ml. The results of a
protection test using this material are
shown in Fig. 3. The challenge dose
was 103 cells anid the treatment consisted
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FIG. 3. Protection of Balb/c mice against SB1 cells, challenge dose 103, i.p. Treatment, injections
ip. 4 h after challenge and again at 24 h intervals 3 times with: normal mouse serum (0.4 ml),
O O; undiluted, absorbed alloantiserum from C3H mice (0-25 ml), A A; Ig prepared
from that antiserum, (2 mg) a 0; the same amplified by 0-2 mg chlorambucil, * *.
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FIG. 4. Protection of C57BL/6 mice against EL4 lymphoma cells, challenge dose 5 x 104. Treat-
ment, injections i.p. 18 h after challenge and again at 24 h intervals 4 times with: normal rabbit
serum (0-5 ml), 0 O; absorbed rabbit anti-EL4 serum (0-5 ml), A A; Ig from the anti-
serum (5 mg), C- LI; chlorambucil (75 ,Ig), * *; chlorambucil (75 ,ug) followed by Ig
from antiserum (5 mg), A A.
of 4 injections of serum, the first at
4 h and 3 times at 24 h intervals there-
after. It can be seen that fractionated
antibody at 2 mg doses was somewhat
less effective than whole antiserum (0.5 ml
doses), but the effect of antibody could
be magnified to make it more obvious
by also injecting a small amount of
chlorambuciL (0-2 mg) an hour before
antibody was injected, this being an
insufficient quantity of drug to affect
the issue when used alone. This topic
is discussed more fully in a later report
by Davies et at. (1974a).
The xenogeneic system
An example of the final protection
test system arrived at is as follows: A
rabbit serum (R85/86) was used, resulting
from 6 intravenous injections of 108 living
EL4 cells. The serum was heat inactivat-
ed (56TC for 30 min) and the yield of
38 ml was diluted 1: 2 in saline, absorbed
as indicated previously and fractionated
to crude Ig with AmSO4. The absorption
data are given in Table I. Fig. 4showsthat
protection can be obtained with xeno-
antiserum fractionated to Ig and absorbed
in vitro to zero cytotoxicity for normal
TABLE I.-Sequential Absorption of Rabbit
Anti-EL4 Serum*
Absorbed with
1 50 livers and spleens
2 50 livers and spleens
3 300 spleens
4 720 spleens
5 280 spleens
Titre (original 1: 1500)
1: 420
1: 300
1: 200
1: 30
zero
* Vol. of 136 ml at dilution 1: 2, absorbed
overnight at 4°C.
u
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lymphoid cells. The time lapse between
challenge and treatment can then be
increased substantially over that which
can be achieved with alloantiserum; in
this example it was 18 h.
Tumour specific antibody
A series of protection tests showed
that the potency of different antisera
and the ease (or difficulty) with which
they could be absorbed differed with
the number of immunizing injections.
This was tested as follows: rabbits
(R96198) were injected i.v. with 108 live
EL4 cells 5 times at 10 day intervals
and bleedings of 40 ml taken before the
second and each subsequent injection.
The resulting 5 antisera were heat in-
activated and cytotoxicity for normal
cells was reduced to zero by absorption as
shown in Table II. Using samples of
these absorbed sera (checked with rabbit
complement and a 3 h incubation time),
the titres against EL4 cells varied as
shown in Table II. These sera were
then examined for their ability to give
immunofluorescence ofEL4 cells (checking
for non-reactivity with normal C57BL/6
cells as control) using a goat Ig anti-
rabbit Ig. The results showed no fluo-
rescence after the first bleeding, a little
after bleeding 2, maximal fluorescence
after bleeding 3 and persisting submaxim-
ally in bleedings 4 and 5. Ammonium
sulphate fractionation results are also
shown in this Table.
The Ig from each bleeding was ad-
justed to 20 mg/ml for protection testing.
A challenge dose of 5 X 104 EL4 cells
was given intraperitoneally and 0-2 ml
(4 mg) of antibody was given 4 times, the
first being 6 h after challenge and then
after 24, 48 and 72 h. Thus, the test
was made less severe by reducing the
time lapse from 18 h (as in the previous
test) to 6 h, increasing sensitivity to
seek smaller amounts of protective acti-
vity. It can be seen from Fig. 5 that
the first bleeding had some activity but
less than the second, the third was
TABLE II.-Successive Bleedings from
Rabbits Immunized with Mouse EL4
Lymphoma
No. of spleens/2 ml of
1: 2 serum to absorb Residual
for zero titre against titre*
Bleed- normal lymphocytes against Yield
ing A EL4 (mg)
no. 1st 2nd 3rd 4th cells ofIg
1 10 10 0 0 Nil 113
2 10 10 10 0 1: 12 133
3 10 10 10 5 1 :30 105
4 10 10 10 10 Nil 104
5 10 10 10 0 Nil 122
* Incubation time 3 h using guinea-pig com-
plement, cells not neuraminidase-treated.
maximal and the fourth and fifth had
decreasing protective action.
The SB1 system gave a different
result. Rabbits 93/95 were given 10
injections of 108 SB1 cells intravenously
and bleedings of 40 ml were taken 10
days before the second and each subse-
quent injection. Samples (1 ml) of these
bleedings were diluted 1: 2 in saline and
the cytotoxicity absorbed out; the number
of absorptions required to reduce cyto-
toxicity for normal cells to zero increased
up to the third bleeding and subsequently
decreased. With these data as a guide,
bulk absorptions and fractionation to Ig
were carried out. These Ig fractions
were all adjusted to 20 mg/ml and used
in a protection test where mice were
challenged with 103 cells intraperitoneally
and given 4 mg of antibody (0.2 ml) 4
times in an " easy " system, i.e. treatment
2 h before, 4 h after and 28 and 56 h
after challenge. The result is not illus-
trated; some protective activity could be
detected using serum taken after the
fifth and sixth injections only. Cyto-
toxicity against SB1 cells in sera having
no residual reactivity against normal
Balb/c lymphocytes was detectable only
in the fifth bleeding.
Class of antibody
A pool of rabbit anti-EL4 sera (R140/
145) was heat inactivated (56°C for
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FIG. 5.-Protection of C57BL/6 mice against EL4 lymphoma, challenge dose 5 x 104 cells. Treat-
ment, injections i.p. 6 h after challenge and again 24, 48 and 72 h later, with 4 mg Ig from serum
raised in rabbits. Rabbits bled 1 day before the secon(d and each of 4 subsequent injections
(108 EL4 cells each time i.v.). Controls (injected with buffered saline), 0 O; first bleedling,
A A; second, C: O; third, 0 0; fourth, A A; fifth, * U.
30 min), absorbed to provide only tumour
specificity and a 12 ml sample passed
through a Sephadex G-200 column (1 m x
5 cm, capacity 2-2 1) in 01 mol/l-
NH4HCO3 at pH 8 0. Three pools were
made from the 280 nm O.D. pattern-
excluded (Pool A), retarded (Pool B)
and included (Pool C), each reduced to
the original vol (12 ml) and dialysed
against saline; these we take to be IgM,
IgG and albumin respectively in the gross
sense.
These were assessed in a protection
test where C57BL/6 mice were challenged
with 5 x 104 EL4 cells i.p. and treated
with serum G-200 Sephadex fractions in
0 5 ml doses 18 h later and again on the
following 3 days. The results of this
test are not illustrated. Original serum
(also 0 5 ml doses) provided for a 12 day
increase in life span; the IgG fraction
(Pool B) gave the same result. Pools A
and C gave no protection against tumour
growth; these mice died at 12 to 16 days
after challenge, as did controls given
normal mouse serum.
Specificity
Whereas we have assessed a number
of mouse tumours for their usefulness in
test systems of the kind described above,
only EL4 and SB1 have been quoted in
this paper. An experiment was carried
out which showed lack of interaction
between EL4 and SB1 systems; a further
21
specificity control using the H-2b lymph-
oma ERLD which, like EL4, belongs to
C57BL/6 mice (Old et al., 1968) was
also carried out. A rabbit anti-EL4
serum (R140/145) was used as described
above to show that 0 5 ml given 4 times
affected the growth of EL4 in C57BL/6
mice adversely and prolonged the lives
of mice in this particular test for 9 days
(prolongation from Day 15 to Day 24).
In the same test, batches of mice were
also challenged with ERLD (1 x 105,
i.p.); this dose and drug levels were based
on ERLD background data of the kind
shown in Fig. 1 for EL4 and SB1 and in
the following paper describing the drug
antibody (" DRAB ") effect (Davies et
al., 1974a). No protection against ERLD
was obtained with anti-EL4 antiserum,
and small doses of chlorambucil in
addition did not show the amplification
effect (as seen in Fig. 3 and 4), presumably
because there was nothing to amplify.
DISCUSSION
Protection tests as used by Gorer and
Amos (1956) and many other workers in
slightly different regimens and with dif-
ferent tumours have been described fre-
quently in the literature. Thus, for
example, fractions of EL4 cells were
tested for the presence of tumour specific
antigen; fractions were injected for active
immunization of other mice to obtain
allogeneic antisera to test for the presence
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of protective antibody (Davies, 1963).
The results showed that tumour specificity
(" X ") was located in or on the plasma
membranes of EL4 tumour cells. Any
clinical use of antibody, either alone or
in combination with some other treat-
ment, requires assessment in some animal
model. There is no special novelty about
the model described here, it was merely
arranged, to suit our particular require-
ments, by extending (a) to another
tumour (SBI), (b) from alloantisera to
xenoantisera, (c) to the use of Ig rather
than whole serum, and (d) to absorption
in vitro instead of in vivo. These steps
worked satisfactorily and have since been
used with human material to provide
tumour specific immunoglobulin (O'Neill,
results to be published).
It will be seen that the number of
injections to elicit the best anti-tumour
response is both critical and difficult to
determine. The number differs from one
tumour to another, as seen by direct
testing in vivo. It then becomes of great
importance to have some in vitro method
of assessment and it is interesting to
see that both cytotoxicity for EL4
tumour cells (when it was zero for normal
cells) and immunofluorescence ran parallel
with protective activity when the three
were tested on each of a series of antisera.
A different number of injections required
for the lymphoma SB1 also gave cor-
relation between cytotoxicity and pro-
tection.
Gel filtration was used to show that
the tumour specific xenoantibody respon-
sible for protection was not IgM but was
in the IgG fraction.
The adjustment of the tests from
severe to relative ease as required was
achieved by altering the challenge dose,
the time lapse between challenge and
treatment, or the number and size of
treatment injections.
The amplification of the protective
effect of antibody by drugs, which was
touched on in this paper is expanded
upon in a later communication (Davies et
al., 1974a).
We wish to thank Mr Richard Sugar
for carrying out the immunofluorescence
studies.
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